Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
API
0
FDF
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. 2-((5-chloro-2-(4-((4-methylpiperazin-1-yl)methyl)anilino)pyrimidin-4-yl)amino)-n,n-dimethylbenzenesulfonamide
2. Dubermatinib
3. Tp-0903
4. Tp0903
1. Dubermatinib
2. Tp-0903
3. 1341200-45-0
4. Tp0903
5. Tp 0903
6. Dubermatinib [usan]
7. Chembl2022968
8. Hcl-2084
9. Compound 13
10. 14d65tv20j
11. 2-[[5-chloro-2-[4-[(4-methylpiperazin-1-yl)methyl]anilino]pyrimidin-4-yl]amino]-n,n-dimethylbenzenesulfonamide
12. Dubermatinib [inn]
13. Dubermatinib [who-dd]
14. Unii-14d65tv20j
15. Gtpl8863
16. Schembl12813478
17. Ex-a609
18. Amy10826
19. Bcp15884
20. Bdbm50382425
21. Mfcd28502172
22. Nsc798200
23. Who 10925
24. Zinc84617535
25. Akos026750306
26. Ccg-269819
27. Cs-4281
28. Db15187
29. Nsc-798200
30. Sb17174
31. Ncgc00481577-01
32. Ac-30945
33. As-55868
34. Da-45909
35. Hy-12963
36. Ft-0700169
37. S7846
38. A900291
39. J-690134
40. Q27089011
41. 2-{[5-chloro-2-({4-[(4-methylpiperazin-1-yl)methyl]phenyl}amino)pyrimidin-4-yl]amino}-n,n-dimethylbenzene-1-sulfonamide
42. 35-chloro-n,n,74-trimethyl-2,4-diaza-3(4,2)-pyrimidina-7(1)-piperazina-1(1),5(1,4)-dibenzenaheptaphane-12-sulfonamide
43. Benzenesulfonamide, 2-((5-chloro-2-((4-((4-methyl-1-piperazinyl)methyl)phenyl)amino)-4-pyrimidinyl)amino)-n,n-dimethyl-
| Molecular Weight | 516.1 g/mol |
|---|---|
| Molecular Formula | C24H30ClN7O2S |
| XLogP3 | 3.9 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 8 |
| Exact Mass | 515.1870221 g/mol |
| Monoisotopic Mass | 515.1870221 g/mol |
| Topological Polar Surface Area | 102 Ų |
| Heavy Atom Count | 35 |
| Formal Charge | 0 |
| Complexity | 752 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
A Dubermatinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dubermatinib, including repackagers and relabelers. The FDA regulates Dubermatinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dubermatinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Dubermatinib supplier is an individual or a company that provides Dubermatinib active pharmaceutical ingredient (API) or Dubermatinib finished formulations upon request. The Dubermatinib suppliers may include Dubermatinib API manufacturers, exporters, distributors and traders.
Dubermatinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Dubermatinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Dubermatinib GMP manufacturer or Dubermatinib GMP API supplier for your needs.
A Dubermatinib CoA (Certificate of Analysis) is a formal document that attests to Dubermatinib's compliance with Dubermatinib specifications and serves as a tool for batch-level quality control.
Dubermatinib CoA mostly includes findings from lab analyses of a specific batch. For each Dubermatinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Dubermatinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Dubermatinib EP), Dubermatinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dubermatinib USP).
LOOKING FOR A SUPPLIER?
